Ascletis
Hangzhou · Founded 2011
About Ascletis
Ascletis is a joint venture between U.S. and Chinese entrepreneurs aimed at building a global specialty therapeutics business dedicated to discovering and developing important new treatments for cancer and infectious diseases. Ascletis leverages U.S./European innovation and pharmaceutical/biotech strategic experience and China's capital efficiency with a goal of establishing in the near term a sustainable business and accelerated revenues through the in-licensing, late-stage clinical development, and commercialization of new medicines for the growing Chinese pharmaceutical marketplace. At the same time, the company is building long-term value through the discovery, demonstration of clinical proof-of-concept, and global partnering of novel therapeutics for life-threatening diseases.
Company Facts
- Founded: 2011
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $255.0M
- Funding stage: IPO
- Last round: Series B (Jan 2017)
- Ticker: hkg:1672.HK
- Website: http://www.ascletis.com
- Phone: 1-919-328-0212
Industries & Categories
Health Care, Medical, Therapeutics
Investment Activity
- 1 exit(s) (1 via IPO)
Social Profiles
Canonical: https://fsome.com/organization/ascletis-93230 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.